Perrigo Company plc (NYSE:PRGO) Receives Consensus Rating of “Hold” from Analysts

Shares of Perrigo Company plc (NYSE:PRGO) have earned a consensus rating of “Hold” from the six ratings firms that are currently covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and one has given a buy rating to the company. The average twelve-month price target among brokers that have issued a report on the stock in the last year is $19.3333.

A number of research firms recently weighed in on PRGO. Weiss Ratings raised shares of Perrigo from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday, June 15th. Zacks Research upgraded Perrigo from a “strong sell” rating to a “hold” rating in a research note on Monday, April 27th.

Perrigo Stock Down 0.1%

Perrigo stock traded down $0.01 during trading on Friday, reaching $11.01. 3,336,041 shares of the company’s stock were exchanged, compared to its average volume of 4,488,991. Perrigo has a 52-week low of $9.23 and a 52-week high of $28.43. The firm has a market cap of $1.52 billion, a price-to-earnings ratio of -0.84, a PEG ratio of 1.31 and a beta of 0.51. The company has a debt-to-equity ratio of 1.45, a quick ratio of 1.59 and a current ratio of 2.72. The company’s 50-day moving average is $10.89 and its two-hundred day moving average is $12.12.

Perrigo (NYSE:PRGO) last issued its quarterly earnings data on Wednesday, May 6th. The company reported $0.43 EPS for the quarter, topping analysts’ consensus estimates of $0.39 by $0.04. Perrigo had a positive return on equity of 9.96% and a negative net margin of 43.50%.The company had revenue of $841.80 million for the quarter, compared to analysts’ expectations of $1.04 billion. During the same quarter in the previous year, the firm posted $0.60 earnings per share. The firm’s quarterly revenue was down 7.2% on a year-over-year basis. Perrigo has set its FY 2026 guidance at 2.250-2.550 EPS. On average, analysts predict that Perrigo will post 2.11 earnings per share for the current year.

Perrigo Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Tuesday, June 16th. Shareholders of record on Friday, May 29th were given a $0.29 dividend. This represents a $1.16 dividend on an annualized basis and a dividend yield of 10.5%. The ex-dividend date of this dividend was Friday, May 29th. Perrigo’s dividend payout ratio is presently -8.85%.

Institutional Trading of Perrigo

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Amundi lifted its holdings in shares of Perrigo by 11.7% during the first quarter. Amundi now owns 5,292 shares of the company’s stock worth $148,000 after buying an additional 556 shares in the last quarter. Kestra Investment Management LLC increased its position in Perrigo by 57.1% during the second quarter. Kestra Investment Management LLC now owns 1,766 shares of the company’s stock worth $47,000 after acquiring an additional 642 shares during the period. Geneos Wealth Management Inc. raised its stake in Perrigo by 439.1% in the 1st quarter. Geneos Wealth Management Inc. now owns 965 shares of the company’s stock worth $27,000 after purchasing an additional 786 shares in the last quarter. EverSource Wealth Advisors LLC boosted its holdings in Perrigo by 116.0% in the 4th quarter. EverSource Wealth Advisors LLC now owns 1,888 shares of the company’s stock valued at $26,000 after purchasing an additional 1,014 shares during the period. Finally, Rafferty Asset Management LLC grew its position in shares of Perrigo by 9.7% during the 3rd quarter. Rafferty Asset Management LLC now owns 12,153 shares of the company’s stock worth $271,000 after purchasing an additional 1,071 shares in the last quarter. Institutional investors own 95.91% of the company’s stock.

Perrigo Company Profile

Perrigo Company plc is a global healthcare supplier specializing in over-the-counter (OTC) and self-care products, as well as generic prescription pharmaceuticals and active pharmaceutical ingredients. The company develops, manufactures and distributes a broad array of consumer health products, including analgesics, vitamins and supplements, digestive health remedies, topical treatments, and infant formulas. Perrigo’s focus on private-label solutions has made it a leading partner for retailers and pharmacy chains seeking high-quality, value-oriented alternatives to branded medications and health supplements.

Organized across three principal business segments—Consumer Healthcare, Prescription Pharmaceuticals and Active Pharmaceutical Ingredients—Perrigo’s operations span research and development, manufacturing, quality assurance and global distribution.